The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a ...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced ...

Alzheimer’s disease (AD) is a serious neurodegenerative disease largely affecting older adults. Apart from age, it also shows ...

A protein once thought to simply help cancer cells avoid death turns out to do much more. MCL1 actively drives cancer ...

ProQR is developing RNA therapies based on its proprietary Axiomer RNA editing technology platform. The ongoing Phase 1 study of AX-0810, which targets NTCP for cholestatic diseases such as primary ...

A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

Scientists have uncovered evidence that two defining features of cancer are driven by the same underlying molecular process. These features include ...